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A B S T R A C T  
Objective: To compare the efficacy of prophylactic enteral probiotic administration versus placebo in the prevention of 
necrotizing enterocolitis in preterm infants. 
Patients and Methods: This randomized control trial was carried out at Paediatric Department of Holy Family Hospital, 
Rawalpindi. A total of 154 preterm infants, 28-33 weeks’ gestational age and <2500 grams at birth were enrolled after 
informed parental consent a donation of for 6 months. They were randomized in to 2 groups with 77 in each group. The 
infants in the study group were given BILUS (B.bifidus & L.acidophilus) with breast milk twice a day. The infants in the 
control group were given breast milk alone. Physical and radiological signs of Necrotizing Enterocolitis (NEC) were 
observed and NEC was staged according to Modified Bell’s criterion. 
Results: The frequency of Necrotizing Enterocolitis was lower in the study group as compared to the control group; 4 of 
77 (5.2%) versus 6 of 77(7.8%) but the results were not statistically significant (p value = 0.25) 
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I n t r o d u c t i o n  
 
Necrotizing enterocolitis (NEC) is one of the most 
common gastrointestinal emergencies in the newborn 
infants.  It is one of the most devastating life-threatening 
diseases affecting 7 to 14% of preterm infants.1 Not only 
is it associated with high mortality but also with long-term 
adverse outcomes such as neurodevelopmental 
impairment in the survivors.2 The precise pathogenesis is 
unknown and it is considered as multifactorial disease. 
Three major factors are thought to contribute i.e. 
presence of pathogenic organisms, altered enteric 
mucosal integrity and the challenge of enteral feeding.3 A 
better understanding of the intestinal ecosystem in 
preterm babies may hold the key to prevention of NEC. 
The microflora in the gut of preterm baby lacks the 
biodiversity that is seen within days in a healthy baby born 
at term.4 One factor may be the late introduction of breast 
milk, that contains bifidobacteria which promote healthy 
microbiota development.5 Probiotics are live microbial 
agents that are delivered enterally, colonize the gut and 
provide benefits to the host. As it takes time for the gut of 
preterm babies to be colonized by beneficial bacteria that 
contribute to healthy gut function, early prophylactic 
treatment with probiotics seems a very logical strategy.6 
Probiotics may assist in establishing a normal non-
pathologic flora by preventing the binding of pathogenic 
bacteria to the enterocyte, local production of 
antimicrobial products or by altering the intestinal luminal 
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pH, by producing potentially microbicidal short chain 
volatile fatty acids.7 Genomic studies of the probiotic 
lactobacillus rhamnosus have revealed that it contains 
pilus fibers with mucus binding predisposition by which it 
displaces pathogenic bacteria.8 These data suggest that 
probiotics by modifying the occurrence of cascade of 
events may play a major role in reducing the incidence of 
NEC. Various probiotics have been used for this purpose 
but the most commonly employed are species of 
bifidobacteria and lactobacillus.9  
In this study, we evaluated the role of probiotics 
(bifidobacteria and lactobacillus) in the prevention of 
necrotizing enterocolitis in preterm infants. The results of 
some previous studies are quite encouraging but more 
studies are needed so that probiotic administration can be 
made a routine protocol in the care of preterm infants.   
    P a t i e n t s  a n d  M e t h o d s  
This randomized control trial was carried out in the 
nursery of Paediatric Department of Holy Family Hospital, 
Rawalpindi from 10th September 2010 to 9th March 2011. 
Premature infants with gestational age between 28 and 
33 weeks, weighing <2500 grams who started to feed 
enterally and survived beyond the seventh day after birth 
were included in the study and those with necrotizing 
enterocolitis developed within 7 days of birth were 
excluded. Approval of this study was taken by the ethical 
committee of Rawalpindi Medical College and allied 
hospitals. Informed parental consents were taken. About 
154 preterm infants were randomized into the study group 
and control group with 77 in each group. Randomization 
was done by consecutive non-probability sampling. The 
study group was given Bilus which contains 
Bifidobacterium Bifidus and lactobacillus acidophilus 1 x 
106 CFU each.  This was mixed with expressed breast 
milk and given twice a day. The control group received 
breast milk alone. This was administered by the nursing 
staff via nasogastric tube. 
Feeding was started when the infant had stable vital 
signs, active bowel sounds, visibly normal abdomen and 
with no dirty or bloody aspirate. Strict feeding protocol 
was followed. Depending on the birth weight and 
gestational age feeding was started. The feeding was 
advanced slowly with daily increment of   15-20ml/kg. The 
probiotic was added when feeding was tolerated usually 
by fifth or sixth day of life. During this time infants’ vitals, 
i.e. heart rate, respiratory rate, the temperature was taken 
daily and were examined for feeding intolerance, 
abdominal distension, bloody stools, and emesis. 
Abdominal distension and any residual feed were 
checked by nursing staff before each feed. If present, was 
reported to doctor and feeding was stopped if residual 
feed was more than 30% of last feed.  Laboratory 
parameters that were done in all cases were complete 
blood count, electrolytes, and stool routine examination. 
Blood and stool cultures along with x-rays were done in 
suspected cases of NEC. NEC was categorized according 
to modified Bell’s criterion. 
Patients were monitored for a period of two weeks or until 
discharge/death.  A proforma was filled for all of the study 
participants. SPSS version 14.0 was used to enter and 
analyze the data. Chi-Square test was used on 
categorical variables like efficacy in both groups. The 
significance level was assumed to be any value less than 
0.05.  
R e s u l t s  
In probiotic group, the mean age of patients was 5.29 
days + 0.51 SD and was 5.30 days + 0.54 SD in the 
control group. The average birth weight was 1498.7 
grams + 214.3 SD in the probiotic group and 1461.0 
grams + 206.6 SD in the control group. When birth weight 
was compared in categories, 42 (54.5%) in probiotic 
group had low birth weight while in control group 
32(41.6%) had low birth weight. Similarly, in probiotic 
group 35 (45.5%) had VLBW while in the control group 45 
(58.4%) had VLBW. (Table 1).  
Table 1.  Baseline characteristics of patients in the two 
study groups 
 
Probiotic group Control group 
(n = 77) (n = 77) 
Age (days) 
Mean + SD 5.29 + 0.51 5.30 + 0.54 
Birth weight (grams) 
 Mean + SD 1498.7 + 214.3 1461.0 + 206.6 
Weight in categories 
LBW   n (%) 42 (54.5) 32 (41.6) 
VLBW   n (%) 35 (45.5) 45 (58.4) 
 
The mean gestational age in the probiotic group was 31.5 
+ 1.5, weeks compared to 31.3 + 1.5 weeks in the control 
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group. The categories according to gestational age were 
also compared. (Table 2) 
Table 2. Gestational age of preterm babies in the two 
study groups 
 
Probiotic 
group 
(n = 77) 
Control 
group 
(n = 77) 
Gestational age 
(weeks) 
    Mean + SD 
 
31.5 + 1.5 
 
31.3 + 1.5 
Gestational age in 
categories (n%) 
    < 30 weeks 
    30 – 31 weeks 
    32 – 33 weeks 
 
 
11 (14.2) 
16 (20.8) 
50 (65.0) 
 
 
11 (14.2) 
29 (37.7) 
37 (48.1) 
The clinical signs like temperature, heart rate and 
respiratory rate were compared in both study groups, and 
were found to be statistically insignificant. Similarly, 
lethargy, feeding intolerance and abdominal distension 
were compared. Emesis and bowel sounds were also 
noted (Table 3).  
Table 3.  Comparison of clinical signs of patients in the 
two study groups 
Clinical 
signs 
Probiotic group 
(n = 77)  
Control group 
(n = 77)  
p-
value 
 Temperature  
 Normal  
 Hyperthermia 
 Hypothermia  
 Unstable  
n (%) 
74 (96.1) 
2 (2.6) 
0 (0.0) 
1 (1.3) 
n (%) 
71 (92.2) 
0 (0.0) 
2 (2.6) 
4 (5.2) 
 
 
   0.21 
 
 Respiratory rate n(%) 
 Normal  73 (94.8) 72 (93.5) 0.45 
 Apnea  1 (1.3) 0 (0.0)  
 Tachypnea  3 (3.9) 5 (6.5)  
 Heart rate n(%) 
 Normal  74 (96.1) 71 (92.2) 0.58 
 Bradycardia  2 (2.6) 4 (5.2)  
 Tachycardia  1 (1.3) 2 (2.6)  
Lethargy 
n(%) 
5 (6.5) 6 (8.0) 0.72 
Feeding 
intolerance 
5 (6.5) 6 (8.0) 0.72 
Abdominal 
distension  
5 (6.5) 6 (8.0) 0.72 
Emesis  4 (5.2) 6 (8.0) 0.48 
Bowel 
sounds  
3 (3.9) 2 (2.7) 0.67 
Bleeding P/R  5 (6.5) 5 (6.5) 0.96 
 
Comparison of haemoglobin, serum electrolyte and total 
leukocyte count in both groups, was also statistically 
insignificant. (Table 4) Investigations on stool and 
abdominal x-rays were done in both study groups; though 
the difference in proportions of stool R/E results between 
both the study groups was evident, still it could not be 
proven statistically. On stool culture, growth of Klebsiella 
and E-coli were noted. X-ray abdomen findings were 
almost similar among study groups (Table 4).  
Table 4.  Comparison of pathological investigations in the 
two study groups 
Investigations 
 
Probiotic 
group (n=77) 
n (%) 
Control 
group (n=77) 
n (%) 
p-
value 
Hemoglobin   
Normal 
Abnormal 
Serum electrolytes 
    Normal  
    Abnormal 
TLC 
    Normal 
    Decreased 
    Increased  
 
75 (97.4) 
2 (2.6) 
 
73 (94.8) 
4 (5.2) 
 
73 (94.8) 
3 (3.9) 
1 (1.3) 
 
72 (93.5) 
5 (6.5) 
 
71 (89.6) 
6 (7.8) 
 
71 (92.2) 
6 (7.8) 
0 (00) 
 
0.51 
 
 
0.28 
 
 
0.49 
 
 
Stool R/E  
Normal 
Abnormal  
 
73 (94.8) 
4 (5.2) 
 
69 (89.6) 
8 (10.4) 
 
0.27 
Stool Culture  
No Growth  
E-coli 
Klebsiella  
 
76 (98.7) 
0 (0.0) 
1 (1.3) 
 
73 (94.8) 
2 (2.6) 
2 (2.6) 
 
 
0.4 
 
Abdominal X-ray  
Normal 
Distended bowel loops  
Pneumatosis intestinalis 
Ascites   
 
72 (93.5) 
3 (3.9) 
2 (2.6) 
0 (0.0) 
 
71 (92.2) 
3 (3.9) 
2 (2.6) 
1 (1.3) 
 
0.43 
In group study 4 (5.2%) patients developed NEC, while in 
the control group 6(7.8%) patients developed NEC and all 
of these were in 2nd stage of necrotizing enterocolitis. The 
difference in the proportions was evident, however, was 
statistically insignificant. (Table 5)  
Table 5. Comparison of stages of Necrotizing 
enterocolitis between the two study groups 
  Probiotic group Control group  
(n=77)  
n(%) 
(n=77)  
n(%) 
p-value 
Without NEC  73 (94.8) 
 
71 (92.2) 
 
0.74 
NEC stages*    
    Stage 1  1 (1.3) 0 (0.0)  
    Stage 2  2 (2.6) 6 (7.8) 0.25 
    Stage 3  1 (1.3) 0 (0.0)  
*  Probiotics decreases the risk of NEC RR (95% CI) 0.67 (0.20 
– 2.27) 
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D i s c u s s i o n  
Our study shows that prophylactic probiotics 
(bifidobacterium bifidus and lactobacillus acidophilus) are 
not effective in reducing the frequency of NEC. Although 
the difference in cases of NEC in both groups is evident 
(5.2% in the study group as compared to 7.8% in control 
group) but this was not statistically significant. A total of 
10 patients developed NEC out of which 8 had stage 2 
NEC, 1 had stage 1 NEC and 1 had stage 3.  The results 
imply that larger sample size may be required to prove 
that probiotics reduce the incidence of NEC and achieve 
significant results. However, there could be other factors 
to account for these results. 
Firstly, the study was not powered to detect stool 
colonization by probiotic bacteria. Stool colonization by 
probiotic bacteria is the means of assessing the viability of 
probiotic species. This can be equated for checking the 
bioavailability of a drug. The viability of probioic bacteria 
was checked by this method by Lin et al in their pilot 
study.10 Secondly, there are many variables associated 
with the development of NEC. The consistent ones are 
prematurity and low birth weight.11 The other risk factors 
that are associated with increased risk of NEC are vaginal 
delivery, need for ventilatory support, low APGAR score 
at 5 minutes.12 The study was randomized but these risk 
factors were not accounted for, as all preterm infants in 
the study were not hospital born and thus the complete 
data was not available in those cases. 
Thirdly, the difference in results could be because of the 
dose used. The dose used in our study was 1x 106 CFU. 
Although there is no fixed dose of the probiotics used in 
various studies nor is the dosing interval determined but it 
seems that increasing the dose to 109 CFU has better 
results. In his first study Lin et al used probiotics in a dose 
of 1 x 106 CFU, however in the second study by Lin et al 
the dose used was 2 x 109  CFU  and Samanta et al also 
gave a probiotic mixture in a dose of 2.5 x 109 CFU but 
the probiotics used were also different.10,13 The results of 
our study are in accordance with the study done by Dani 
et al in which although NEC was found less frequent in 
the probiotic  group i.e. 1.4% in the probiotic group versus 
2.7% in the study group, the results were not significant.14 
Another study was done in USA in 2009, in which the 
effect of two probiotic and prebiotic products on weight 
gain, stool microbiota and stool short chain fatty acids 
was assessed. NEC was a secondary outcome. There 
were 3 groups, 2 of which received probiotic preparation 
but the probiotic did not decrease the incidence of NEC.15 
The results of our study are also in accordance with the 
study in Turkey in 2011, in which lactobacillus sporogenes 
was given to 110 infants until discharge. It was seen that 
there was no difference in the incidence of NEC in the 
probiotic supplemented as compared to the control 
group.16 In our study, it was seen that most cases of NEC 
i.e. 5 out of 10 (50%) occurred in one month, the month of 
November. It has been reported in different studies that 
many cases of NEC occur sporadically, however, NEC 
epidemics have also been reported in literature. In a 
retrospective study carried out at two neonatal intensive 
care units in Cincinatti USA, data regarding the 
occurrence of NEC was analyzed over an 8-year period. It 
was found that there were 12 temporal clusters of NEC 
which comprised  18%  of  total  203  cases.17 Our study 
did not focus on improvement in feeding tolerance with  
probiotics, but a number of studies have focussed on this 
aspect and  provide encouraging results. A study done by 
Samanta et al showed that the number of days required to 
reach full feeds was significantly lower in babies who 
received probiotics (13.76 vs. 19.2).13 Therefore feeding 
tolerance was better. Another study was carried out in 
China, which focused on the same subject. The incidence 
of feeding intolerance in the probiotics treatment group 
was lower than that in the conventional treatment group 
(4% vs 14%; P <0.01) in their study.18 The time to regain 
birth weight (6.8±1.2 days vs 7.7±1.6 days; P<0.05) and 
the time to reach full enteral nutrition (8.0±1.4 days vs 
9.0±2.0 days; P<0.05) in the probiotics treatment group 
were shorter than those in the conventional treatment 
group. 
The extensive and safe use of commercial probiotics 
worldwide over several decades alongside clinical trials to 
assess potential adverse  effects, provide the most 
compelling evidence for the safety of probiotics for the 
general population.19 To date over 2,000 premature 
neonates have been exposed to prophylactic probiotics in 
different prospective studies and no adverse short term 
effects have been noted.20 This history of safe 
consumption of some probiotics has generally been 
considered proof of short term safety for this vulnerable 
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population of infants but the proof of safety of a specific 
strain requires study of that strain rather than 
extrapolation from related strains. The trials mentioned 
earlier did not report any cases of sepsis secondary to 
probiotic use; however, they were not powered to detect 
such cases. The European society for Paediatric 
gastroenterology, hepatology and nutrition’s committee on 
nutrition found limited high-quality data on the safety of 
probiotics added to infant formulas and no long-term 
studies on benefits and adverse effects of such 
supplementation.21 Furthermore, the potential for sepsis 
from probiotics is unknown because the culture media 
used in most diagnostic laboratories do not support the 
fastidious anaerobic probiotic growth.22 
It is not known that which probiotic or probiotic 
combination is best to use. It seems that double or triple 
probiotic strains provide the greatest effect. The 
appropriate dose and the frequency of dosing also need 
to be addressed. The quality of probiotics available is also 
unknown. Each probiotic strain is a unique component 
itself and each strain has specific properties that cannot 
be extrapolated from other, even closely related strains. 
The specific properties of probiotic bacteria need to be 
characterized.22 Thus there are still a lot of things 
unknown about probiotics and concerns regarding its 
safety. Some of the trials done so far, have shown definite 
benefits but other trials like ours have shown inconclusive 
results. Currently, there are 16 randomized controlled 
trials studying 12 different probiotic preparations in 
preterm infants which report data on clinically important 
outcomes such as NEC, mortality, sepsis, or feeding 
advancement. Although the results from these trials are 
encouraging, There is no evidence to recommend that all 
preterm infants should be fed probiotics routinely.23 The 
ability to manipulate enteric microbial flora in preterm, 
very low birth weight infants towards a normal non-
pathogenic microenvironment addresses one of the 
fundamental issues in the pathogenesis of NEC.8 The 
current study is, therefore, an important one and it is 
recommended that further studies are done with a larger 
sample size and enhanced scientific methods.  
C o n c l u s i o n  
Prophylactic probiotics Bilus (Bifidobacterium bifidus and 
lactobacillus acidophilus) given twice a day in a dose of 
1x106 with breast milk for two weeks is not effective in 
reducing the frequency of NEC in  preterm infants. To 
unequivocally prove the clinical efficacy of probiotics in 
NEC large multicenter trials are needed. Our results 
suggest for more research regarding appropriate bacterial 
strain, dose, and timing of administration to achieve 
clinically robust effects and also include analysis of 
possible adverse effects of probiotic administration, such 
as probiotic-associated sepsis and tolerance of milk 
feeding. 
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